Late effects of chronic graft-versus-host disease

Best Practice and Research: Clinical Haematology

Volumn 21, Issue 2, 2008, Pages 309-331

  Carpenter, Paul A ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

chronic GVHD; hematopoietic cell transplantation; late effects

Indexed keywords

ACICLOVIR; ALPHA TOCOPHEROL; ANALGESIC AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT; AZITHROMYCIN; BISPHOSPHONIC ACID DERIVATIVE; CALCINEURIN INHIBITOR; CALCIUM; COTRIMOXAZOLE; CYCLOSPORIN; CYTOTOXIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ESTROGEN; GLUCOCORTICOID; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCRETIN; LONG ACTING INSULIN; METHYLPREDNISOLONE; MONTELUKAST; MUSCARINIC AGENT; PANCREAS ENZYME; PREDNISONE; RETINOL; TACROLIMUS; TRIAZOLE; UNINDEXED DRUG; VITAMIN D;

ADRENAL INSUFFICIENCY; AIRWAY OBSTRUCTION; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTHROPLASTY; ARTIFICIAL VENTILATION; AUTOIMMUNE DISEASE; AVASCULAR NECROSIS; BONE DISEASE; BONE NECROSIS; BRONCHIOLITIS OBLITERANS; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CATARACT; CATARACT EXTRACTION; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CUSHING SYNDROME; CUSHINGOID SYNDROME; CYTOPENIA; DIABETES MELLITUS; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSPHAGIA; EARLY INTERVENTION; EYE DISEASE; FASCIITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL ENDOSCOPY; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTHYROIDISM; HYPOTHYROIDISM; IMMUNOPATHOLOGY; INSULIN RESISTANCE; INTERSTITIAL PNEUMONIA; JOINT CONTRACTURE; KIDNEY FAILURE; LIFESTYLE MODIFICATION; LIVER DISEASE; LIVER TOXICITY; LOW DRUG DOSE; LUNG DISEASE; LUNG FUNCTION TEST; MASSAGE; METABOLIC SYNDROME X; MONOTHERAPY; MOUTH DISEASE; MOUTH HYGIENE; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; MYASTHENIA GRAVIS; MYOPATHY; MYOSITIS; NEPHROTIC SYNDROME; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ODYNOPHAGIA; OPPORTUNISTIC INFECTION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; PANCREAS INSUFFICIENCY; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SYMPTOMATOLOGY; UROGENITAL TRACT DISEASE; WEIGHT REDUCTION;

CHRONIC DISEASE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TIME FACTORS;

EID: 44049104231     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2008.02.016     Document Type: Review

References (121)

1. Stewart B.L., Storer B., Storek J., et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood 104 (2004) 3501-3506
2. Couriel D., Carpenter P.A., Cutler C., et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biology of Blood Marrow Transplantation 12 (2006) 375-396
3. Syrjala K.L., Langer S.L., Abrams J.R., et al. Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma. The Journal of the American Medical Association 291 (2004) 2335-2343
4. Gillis T.A., and Donovan E.S. Rehabilitation following bone marrow transplantation (Review). Cancer 92 (2001) 998-1007
5. Flowers M.E.D., Parker P.M., Johnston L.J., et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 100 (2002) 415-419
6. van Burik J.A., Carter S.L., Freifeld A.G., et al. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease. Biology of Blood Marrow Transplantation 13 (2007) 1487-1498
7. Tichelli A., Duell T., Weiss M., et al. Late-onset keratoconjunctivitis sicca syndrome after bone marrow transplantation: incidence and risk factors. European Group or Blood and Marrow Transplantation (EBMT) working party on late effects. Bone Marrow Transplantion 17 (1996) 1105-1111
8. Takahide K., Parker P.M., Wu M., et al. Use of fluid-ventilated, gas-permeable scleral lens for management of severe keratoconjunctivitis sicca secondary to chronic graft-versus-host disease. Biology of Blood Marrow Transplantation 13 (2007) 1016-1021
9. Benyunes M.C., Sullivan K.M., Deeg H.J., et al. Cataracts after bone marrow transplantation: long-term follow-up of adults treated with fractionated total body irradiation. International Journal of Radiation Oncology, Biology, Physics 32 (1995) 661-670
10. Belkacemi Y., Labopin M., Vernant J.P., et al. Cataracts after total body irradiation and bone marrow transplantation in patients with acute leukemia in complete remission: A Study of the European Group for Blood and Marrow Transplantation. International Journal of Radiation Oncology, Biology, Physics 41 (1998) 659-668
11. Deeg H.J., Leisenring W., Storb R., et al. Long-term outcome after marrow transplantation for severe aplastic anemia. Blood 91 (1998) 3637-3645
12. Aceves S.S., Bastian J.F., Newbury R.O., et al. Oral viscous budesonide: a potential new therapy for eosinophilic esophagitis in children. The American Journal of Gastroenterology 102 (2007) 2271-2279
13. Akpek G., Valladares J.L., Lee L., et al. Pancreatic insufficiency in patients with chronic graft-versus-host disease. Bone Marrow Transplantation 27 (2001) 163-166
14. Grigg A.P., Angus P.W., Hoyt R., et al. The incidence, pathogenesis and natural history of steatorrhea after bone marrow transplantation. Bone Marrow Transplantation 31 (2003) 701-703
15. Kamble R.T., Selby G.B., Mims M., et al. Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biology of Blood Marrow Transplantation 12 (2006) 506-510
16. Stern J.M., Sullivan K.M., Ott S.M., et al. Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study. Biology of Blood Marrow Transplantation 7 (2001) 257-264
17. Carpenter P.A., Hoffmeister P., Chesnut III C.H., et al. Bisphosphonate therapy for reduced bone mineral density in children with chronic graft-versus-host disease. Biology of Blood Marrow Transplantation 13 (2007) 683-690
18. Schimmer A.D., Minden M.D., and Keating A. Osteoporosis after blood and marrow transplantation: clinical aspects (Review). Biology of Blood Marrow Transplantation 6 (2000) 175-181
19. Anonymous. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. American college of rheumatology task force on osteoporosis guidelines. Arthritis and Rheumatism 39 (1996) 1791-1801
20. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. The Journal of the American Medical Association 288 (2002) 321-333
21. Beral V. Million Women SC. Breast cancer and hormone-replacement therapy in the Million Women Study. [erratum appears in Lancet. 2003 Oct 4;362(9390):1160]. Lancet 362 (2003) 419-427
22. Kananen K., Volin L., Laitinen K., et al. Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate. The Journal of Clinical Endocrinology and Metabolism 90 (2005) 3877-3885
23. Socié G., Cahn J.Y., Carmelo J., et al. Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Societe Francaise de Greffe de Moelle (SFGM). British Journal of Haematology 97 (1997) 865-870
24. Tofferi J.K., and Gilliland W. Avascular necrosis. WebMD. Available from (2006). http://www.emedicine.com/med/topic2924.htm
25. Arlet J. Nontraumatic avascular necrosis of the femoral head. Past, present, and future (Review). Clinical Orthopaedics and Related Research (1992) 12-21
26. Fink J.C., Leisenring W.M., Sullivan K.M., et al. Avascular necrosis following bone marrow transplantation: a case-control study. Bone 22 (1998) 67-71
27. Koc S., Leisenring W., Flowers M.E.D., et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 100 (2002) 48-51
28. Pritchett J.W. Statin therapy decreases the risk of osteonecrosis in patients receiving steroids. Clinical Orthopaedics and Related Research (2001) 173-178
29. Pritchett J.W. Statins and dietary fish oils improve lipid composition in bone marrow and joints. Clinical Orthopaedics and Related Research 456 (2007) 233-237
30. Nishii T., Sugano N., Miki H., et al. Does alendronate prevent collapse in osteonecrosis of the femoral head?. Clinical Orthopaedics and Related Research 443 (2006) 273-279
31. Lai K.A., Shen W.J., Yang C.Y., et al. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. Journal of Bone and Joint Surgery - American Volume 87 (2005) 2155-2159
32. Ramachandran M., Ward K., Brown R.R., et al. Intravenous bisphosphonate therapy for traumatic osteonecrosis of the femoral head in adolescents. Journal of Bone and Joint Surgery - American Volume 89 (2007) 1727-1734
33. Agarwala S., Jain D., Joshi V.R., et al. Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study. [erratum appears in Rheumatology (Oxford). 2005 Apr;44(4):569]. Rheumatology 44 (2005) 352-359
34. Castro F.P.J., and Barrack R.L. Core decompression and conservative treatment for avascular necrosis of the femoral head: a meta-analysis. American Journal of Orthopedics (Chatham, Nj) 29 (2000) 187-194
35. Mont M.A., Carbone J.J., and Fairbank A.C. Core decompression versus nonoperative management for osteonecrosis of the hip (Review). Clinical Orthopaedics and Related Research (1996) 169-178
36. Stulberg B.N., Davis A.W., Bauer T.W., et al. Osteonecrosis of the femoral head. A prospective randomized treatment protocol. Clinical Orthopaedics and Related Research (1991) 140-151
37. Koo K.H., Kim R., Ko G.H., et al. Preventing collapse in early osteonecrosis of the femoral head. A randomised clinical trial of core decompression. Journal of Bone and Joint Surgery - British Volume 77 (1995) 870-874
38. Palmas A., Tefferi A., Myers J.L., et al. Late-onset noninfectious pulmonary complications after allogeneic bone marrow transplantation. British Journal of Haematology 100 (1998) 680-687
39. Chien J.W., Martin P.J., Gooley T.A., et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. American Journal of Respiratory and Critical Care Medicine 168 (2003) 208-214
40. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report. Biology of Blood Marrow Transplantation 11 (2005) 945-956
41. Kantrow S.P., Hackman R.C., Boeckh M., et al. Idiopathic pneumonia syndrome: changing spectrum of lung injury after marrow transplantation. Transplantation 63 (1997) 1079-1086
42. Freudenberger T.D., Madtes D.K., Curtis J.R., et al. Association between acute and chronic graft-versus-host disease and bronchiolitis obliterans organizing pneumonia in receipients of hematopoietic stem cell transplants. Blood 102 (2003) 3822-3828
43. Cooke K.R., and Ferrara J.L.M. The pathophysiology of lung injury after hematopoietic stem cell transplantation. Graft-vs-Host Disease. 3rd edn. Vol. 11 (2005), Marcel Dekker, New York, NY 329-367
44. Clark J.G., Schwartz D.A., Flournoy N., et al. Risk factors for airflow obstruction in recipients of bone marrow transplants. Annals of Internal Medicine 107 (1987) 648-656
45. Philit F., Wiesendanger T., Archimbaud E., et al. Post-transplant obstructive lung disease ('bronchiolitis obliterans'): a clinical comparative study of bone marrow and lung transplant patients. The European Respiratory Journal 8 (1995) 551-558
46. Yoshihara S., Yanik G., Cooke K.R., et al. Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and other late-onset noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation. Biology of Blood Marrow Transplantation 13 (2007) 749-759
47. Chien J.W., Martin P.J., Flowers M.E., et al. Implications of early airflow decline after myeloablative allogeneic stem cell transplantation. Bone Marrow Transplantation 33 (2004) 759-764
48. Worthy S.A., Flint J.D., and Muller N.L. Pulmonary complications after bone marrow transplantation: high-resolution CT and pathologic findings (Review). Radiographics 17 (1997) 1359-1371
49. McDonald G.B., Sullivan K.M., Schuffler M.D., et al. Esophageal abnormalities in chronic graft-versus-host disease in humans. Gastroenterology 80 (1981) 914-921
50. Schultz K.R., Green G.J., Wensley D., et al. Obstructive lung disease in children after allogeneic bone marrow transplantation. Blood 84 (1994) 3212-3220
51. Saiman L., Marshall B.C., Mayer-Hamblett N., et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. The Journal of the American Medical Association 290 (2003) 1749-1756
52. Khalid M., Al Saghir A., Saleemi S., et al. Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study. The European Respiratory Journal 25 (2005) 490-493
53. Or R., Gesundheit B., Resnick I., et al. Sparing effect by montelukast treatment for chronic graft versus host disease: a pilot study. Transplantation 83 (2007) 577-581
54. O'Hagan A.R., Stillwell P.C., Arroliga A., et al. Photopheresis in the treatment of refractory bronchiolitis obliterans complicating lung transplantation. Chest 115 (1999) 1459-1462
55. Couriel D.R., Hosing C., Saliba R., et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 107 (2006) 3074-3080
56. Gascoigne A., and Corris P. Lung transplants in patients with prior bone marrow transplants. Chest 105 (1994) 327
57. Rabitsch W., Deviatko E., Keil F., et al. Successful lung transplantation for bronchiolitis obliterans after allogeneic marrow transplantation. Transplantation 71 (2001) 1341-1343
58. Heath J.A., Kurland G., Spray T.L., et al. Lung transplantation after allogeneic marrow transplantation in pediatric patients: the memorial Sloan-Kettering experience. Transplantation 72 (2001) 1986-1990
59. Epler G.R. Bronchiolitis obliterans organizing pneumonia (Review). Archives of Internal Medicine 161 (2001) 158-164
60. Wingard J.R., Santos G.W., and Saral R. Late-onset interstitial pneumonia following allogeneic bone marrow transplantation. Transplantation 39 (1985) 21-23
61. Della Volpe A., Ferreri A.J., Annaloro C., et al. Lethal pulmonary complications significantly correlate with individually assessed mean lung dose in patients with hematologic malignancies treated with total body irradiation. International Journal of Radiation Oncology, Biology, Physics 52 (2002) 483-488
62. Clark J.G., Hansen J.A., Hertz M.I., et al. NHLBI workshop summary: idiopathic pneumonia syndrome after bone marrow transplantation. [Review]. The American Review of Respiratory Disease 147 (1993) 1601-1606
63. Clark J.G., Madtes D.K., Martin T.R., et al. Idiopathic pneumonia after bone marrow transplantation: cytokine activation and lipopolysaccharide amplification in the bronchoalveolar compartment. Critical Care Medicine 27 (1999) 1800-1806
64. Tun H.W., Wallace K.H., Grinton S.F., et al. Etanercept therapy for late-onset idiopathic pneumonia syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation. Transplantation Proceedings 37 (2005) 4492-4496
65. Yanik G., Hellerstedt B., Custer J., et al. Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Biology of Blood Marrow Transplantation 8 (2002) 395-400
66. Arlt W., and Allolio B. Adrenal insufficiency. Lancet 361 (2003) 1881-1893
67. Krasner A.S. Glucocorticoid-induced adrenal insufficiency. The Journal of the American Medical Association 282 (1999) 671-676
68. Oelkers W. Adrenal insufficiency (Review). The New England Journal of Medicine 335 (1996) 1206-1212
69. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. The Journal of the American Medical Association 287 (2002) 356-359
70. Ford E.S., Giles W.H., and Mokdad A.H. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 27 (2004) 2444-2449
71. Nuver J., Smit A.J., Postma A., et al. The metabolic syndrome in long-term cancer survivors, an important target for secondary preventive measures (Review). Cancer Treatment Reviews 28 (2002) 195-214
72. Taskinen M., Saarinen-Pihkala U.M., Hovi L., et al. Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood. Lancet 356 (2000) 993-997
73. Hoffmeister P.A., Storer B.E., and Sanders J.E. Diabetes mellitus in long-term survivors of pediatric hematopoietic cell transplantation. Journal of Pediatric Hematology/Oncology 26 (2004) 81-90
74. Shalitin S., Phillip M., Stein J., et al. Endocrine dysfunction and parameters of the metabolic syndrome after bone marrow transplantation during childhood and adolescence. Bone Marrow Transplantation 37 (2006) 1109-1117
75. Baker K.S., Ness K.K., Steinberger J., et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: A Report from the Bone Marrow Transplantation Survivor Study. Blood 109 (2007) 1765-1772
76. Mertens A.C., Yasui Y., Neglia J.P., et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: The Childhood Cancer Survivor Study. Journal of Clinical Oncology 19 (2001) 3163-3172
77. Chan K.W., Taylor G.P., Shepherd J.D., et al. Coronary artery disease following bone marrow transplantation. Bone Marrow Transplantation 4 (1989) 327-330
78. Gatt M.E., Liebster D., Leibowitz D., et al. Acute myocardial infarction after bone marrow transplantation: an unsuspected late complication. Annals of Hematology 82 (2003) 136-138
79. Ghobrial I.M., Bunch T.J., Caplice N.M., et al. Fatal coronary artery disease after unrelated donor bone marrow transplantation. Mayo Clinic Proceedings. Mayo Clinic 79 (2004) 403-406
80. Barnett A.H., Bain S.C., Bouter P., et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. [erratum appears in N Engl J Med. 2005 Apr 21;352(16)1731]. The New England Journal of Medicine 351 (2004) 1952-1961
81. Strippoli G.F., Craig M., Deeks J.J., et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review (Review). BMJ (Clinical research ed.) 329 (2004) 828
82. Kobashigawa J.A., Katznelson S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. The New England Journal of Medicine 333 (1995) 621-627
83. Holdaas H., Fellstrom B., Jardine A.G., et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 361 (2003) 2024-2031
84. Hingorani S. Chronic kidney disease in long-term survivors of hematopoietic cell transplant: epidemiology, pathogenesis and treatment. Journal of the American Society of Nephrology 17 (2006) 1995-2005
85. Vincent F., Costa M.A., and Rondeau E. Chronic renal failure: a nonmalignant late effect of allogeneic stem cell transplantation. (Letter to the Editor). Blood 102 (2003) 2695-2696
86. Hingorani S.R., Aneja T., Seidel K., et al. Albuminuria in hematopoietic cell transplant (HCT) patients: prevalence and risk factors. Journal of the American Society of Nephrology 17 (2006) 218a #TH-PO818
87. Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002) 1623-1630
88. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. The New England Journal of Medicine 333 (1995) 1301-1307
89. O'Rourke B., Barbir M., Mitchell A.G., et al. Efficacy and safety of fluvastatin therapy for hypercholesterolemia after heart transplantation: Results of a Randomised Double Blind Placebo Controlled Study. International Journal of Cardiology 94 (2004) 235-240
90. Prasad G.V., Ahmed A., Nash M.M., et al. Blood pressure reduction with HMG-CoA reductase inhibitors in renal transplant recipients. Kidney International 63 (2003) 360-364
91. Tsiara S., Elisaf M., and Mikhailidis D.P. Early vascular benefits of statin therapy (Review). Current Medical Research and Opinion 19 (2003) 540-556
92. Fehr T., Kahlert C., Fierz W., et al. Statin-induced immunomodulatory effects on human T cells in vivo. Atherosclerosis 175 (2004) 83-90
93. Prasad G.V., Chiu R., Nash M.M., et al. Statin use and bone mineral density in renal transplant recipients. American Journal of Transplantation 3 (2003) 1320-1321
94. Wang G.J., Cui Q., and Balian G. The Nicolas Andry award. The pathogenesis and prevention of steroid-induced osteonecrosis. Clinical Orthopaedics and Related Research (2000) 295-310
95. Stevens A.M., Sullivan K.M., and Nelson J.L. Polymyositis as a manifestation of chronic graft-versus-host disease (Review). Rheumatology 42 (2003) 34-39
96. Hakim F.T., and Mackall C.L. The immune system: effector and target of graft-versus-host disease. In: Ferrara J.L.M., Deeg H.J., and Burakoff S.J. (Eds). Graft-vs.-Host Disease. 2nd edn. (1997), Marcel Dekker, Inc., New York 257-290 Revised and Expanded
97. Hess A.D. The immunobiology of syngeneic/autologous graft-versus-host disease. In: Ferrara J.L.M., Deeg H.J., and Burakoff S.J. (Eds). Graft-vs.-Host Disease. 2nd edn. (1997), Marcel Dekker, Inc., New York 561-586 Revised and Expanded
98. Rouquette-Gally A.M., Boyeldieu D., Prost A.C., et al. Autoimmunity after allogeneic bone marrow transplantation. Transplantation 46 (1988) 238-240
99. Patriarca F., Skert C., Sperotto A., et al. The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Experimental Hematology 34 (2006) 389-396
100. Lortan J.E., Rochfort N.C., el Tumi M., et al. Autoantibodies after bone marrow transplantation in children with genetic disorders: relation to chronic graft-versus-host disease. Bone Marrow Transplantation 9 (1992) 325-330
101. Karthaus M., Gabrysiak T., Brabant G., et al. Immune thyroiditis after transplantation of allogeneic CD34+ selected peripheral blood cells. Bone Marrow Transplantation 20 (1997) 697-699
102. Lee V., Cheng P.S., Chik K.W., et al. Autoimmune hypothyroidism after unrelated haematopoietic stem cell transplantation in children. Journal of Pediatric Hematology/Oncology 28 (2006) 293-295
103. De Lord C., Marsh J.C., Smith J.G., et al. Fatal autoimmune pancytopenia following bone marrow transplantation for aplastic anaemia. Bone Marrow Transplantation 18 (1996) 237-239
104. Ohashi K., Akiyama H., Takamoto S., et al. Treatment of pure red cell aplasia after major ABO-incompatible bone marrow transplantation resistant to erythropoietin. Bone Marrow Transplantation Team. Bone Marrow Transplantation 13 (1994) 335-336
105. Roychowdhury D.F., and Linker C.A. Pure red cell aplasia complicating an ABO-compatible allogeneic bone marrow transplantation, treated successfully with antithymocyte globulin. Bone Marrow Transplantation 16 (1995) 471-472
106. Selleri C., Raiola A., De Rosa G., et al. CD34+-enriched donor lymphocyte infusions in a case of pure red cell aplasia and late graft failure after major ABO-incompatible bone marrow transplantation. Bone Marrow Transplantation 22 (1998) 605-607
107. Stevenson W.S., Nankivell B.J., and Hertzberg M.S. Nephrotic syndrome after stem cell transplantation. Clinical Transplantation 19 (2005) 141-144
108. Lin J., Markowitz G.S., Nicolaides M., et al. Membranous glomerulopathy associated with graft-versus-host disease following allogeneic stem cell transplantation. Report of 2 cases and review of the literature (Review). American Journal of Nephrology 21 (2001) 351-356
109. Markowitz G.S., Appel G.B., Fine P.L., et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. Journal of the American Society of Nephrology 12 (2001) 1164-1172
110. Glassock R.J. Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum (Review). Journal of the American Society of Nephrology 18 (2007) 2221-2225
111. Kamble R.T., Chang C.C., Sanchez S., et al. Central nervous system graft-versus-host disease: report of two cases and literature review. Bone Marrow Transplantation 39 (2007) 49-52
112. Unger E.R., Sung J.H., Manivel J.C., et al. Male donor-derived cells in the brains of female sex-mismatched bone marrow transplant recipients; a Y-chromosome specific in situ hybridization study. Journal of Neuropathology and Experimental Neurology 52 5 (1993) 460-470
113. Rizzo J.D., Wingard J.R., Tichelli A., et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biology of Blood Marrow Transplantation 12 (2006) 138-151
114. Kelly P., Staunton H., Lawler M., et al. Multifocal remitting-relapsing cerebral demyelination twenty years following allogeneic bone marrow transplantation. Journal of Neuropathology and Experimental Neurology 55 (1996) 992-998
115. Openshaw H., Slatkin N.E., Parker P.M., et al. Immune-mediated myelopathy after allogeneic marrow transplantation. Bone Marrow Transplantation 15 (1995) 633-636
116. Takatsuka H., Okamoto T., Yamada S., et al. New imaging findings in a patient with central nervous system dysfunction after bone marrow transplantation. Acta Haematologica 103 (2000) 203-205
117. Padovan C.S., Bise K., Hahn J., et al. Angiitis of the central nervous system after allogeneic bone marrow transplantation?. Stroke 30 (1999) 1651-1656
118. Greenspan A., Deeg H.J., Cottler-Fox M., et al. Incapacitating peripheral neuropathy as a manifestation of chronic graft-versus-host disease. Bone Marrow Transplantation 5 (1990) 349-352
119. Amato A.A., Barohn R.J., Sahenk Z., et al. Polyneuropathy complicating bone marrow and solid organ transplantation. (Review). Neurology 43 (1993) 1513-1518
120. Smith C.I.E., Aarli J.A., Biberfeld P., et al. Myasthenia gravis after bone-marrow transplantation. Evidence for a donor origin. The New England Journal of Medicine 309 (1983) 1565-1568
121. Sambrook P., Olver I., and Goss A. Bisphosphonates and osteonecrosis of the jaw (Review). Australian Family Physician 35 (2006) 801-803